{"name":"OncoC4, Inc.","slug":"oncoc4-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AI-061","genericName":"AI-061","slug":"ai-061","indication":"Other","status":"phase_1"},{"name":"AI-081","genericName":"AI-081","slug":"ai-081","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AI-061","genericName":"AI-061","slug":"ai-061","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AI-081","genericName":"AI-081","slug":"ai-081","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HU3NUSFNLLVk0YkhnMlR1aHFfdzlSUGFyODJjNGlnX1FVT2JuOExnUHlaZ3B4RVhGeDAzQzlOV2xzOTRRSDRGOEdKTGZaZWZvWk4wZmxsa3JzLUI5djY4?oc=5","date":"2026-03-27","type":"trial","source":"Nature","summary":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial - Nature","headline":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-0","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOS1d5X2ZDZnQ4dUxnSGdKN0lWTjdHX2JzWWdKMk1vSmczWER5XzVHM0VJX2dpVFBEUk1aYldlQkVwSlZCMHl5UUlUQU15U1ZObUtvLW5JNWVLN1VBZEZtNVB6NWZNQU9yVk5obnpPN3dsQlJMcmItaHFoM29pSVhaeFpSbEFyZjdwSUt2OTNlcHY1eXBxaHFxTFZqMjhfMkktUVhweFZpWktGWW9tclBmT0ZacFhKODlVcVMtd3VZQ09LSVFjM2FfcTlreWlHYjdac1p5czJQRC0zbzZ6Ty1aRW9MWEpHSzhBNlBvZks0d3BQbmV4WFE?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart.com","summary":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOckJiWnpHa01WWG5rY3lLVnNZSllQLVVoWVg4NjdYcEo4b3F4N0xkTW5BSm1jdF9DT1hhbGJIdzh2UE9iSFR3dVNkTDE3M0RBSU15bFp2X2dIbll5Y3RZQVFibzI1bS1iSUNEZ21xZG1hS0VLMTRRUFd2MzZfemV6VU8tb1pJeGdsTC11dzB5LUQyUF81TnVwTV9LTQ?oc=5","date":"2025-10-03","type":"pipeline","source":"The Pharma Letter","summary":"OncoC4 closes nearly $50 million Series B financing - The Pharma Letter","headline":"OncoC4 closes nearly $50 million Series B financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB3QUdZNExjbFEwMlRjb01zaHRGWGFoUnhXNFlaUFVlejFheUVWLUd2aTUwc2ppTzlkN2VxbHpsNW5oMHZEbWtHQXExNURTOV9nRldn?oc=5","date":"2025-10-02","type":"pipeline","source":"FirstWord Pharma","summary":"OncoC4 banks $50M to help fuel pipeline push - FirstWord Pharma","headline":"OncoC4 banks $50M to help fuel pipeline push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNb1c4RkpseW8yQzNmMUZTbVBRdk5aNHVWQ2N5R2wxT0c4UEs3eExqa0dUU0Q3cExubXBocGRtQmZMeDZSNDM2SWEzaVVzd1NYa0pEcDJnUHFRYmN4aC1LMmxoSUY5YXdZeWd6eGRtNXJKc2RremctYW91TjdwcE9zZ3lJbmhOVURmYnlBMXg4cHpJQ2Z2N2gxSW9mTWFsRnc?oc=5","date":"2025-10-02","type":"pipeline","source":"The Business Journals","summary":"Rockville biotech OncoC4 closes $50M Series B round - The Business Journals","headline":"Rockville biotech OncoC4 closes $50M Series B round","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOWi1TNGhnN0ZmY3dzblhOQWEtbWZhS0xRSm4xVjVMYVZaRkwwcXBGVU51NjFFRXFST0o1bXhiSEVHYTIzNWhCaUhSUzdzWDNzZC1oWW5ObjFLZVMzOW5WR1c4RlpmQlZ6TUdJYVhjQmdyekVkRi1pdWZpNGxDMFlzZktmbHZGd01XRHZhUThuTmZxOVVKR3F6ck9RQlF2dk82bklWS1RoT0pWRW1vaDJGczd5QWUwSGRqYVdmdkVhQUZDMkpVZzdaUnhua01nRFEzSkUxWHcyc010djR3N3l1NGlkNA?oc=5","date":"2025-10-02","type":"pipeline","source":"prnewswire.com","summary":"OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates - prnewswire.com","headline":"OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQa1JHbXpSQklJQmFLNEZySGMwTGVUYzhzV19OQktoMFM0WDhrWUpzckFJdVZFQXVMSFUxTzEzRjVlUnZ6TEg2bWVIY2Z5aldaTFBnMTYydHdiMXo0ank5SmhVb0pycVJ1dE1DLVR4RWt3eXdFbHpGcVVrREU4MEpSZHhKVFMxUFU?oc=5","date":"2024-10-15","type":"trial","source":"Oncology Pipeline","summary":"Here comes another PD-1/VEGF bispecific | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Here comes another PD-1/VEGF bispecific | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNV9jNHNCVWMtdGNDTjhBTi0wQkhyNnU4a0UycEFqRndsUU5rNUJCUWN3dG85SmU3NUp1a1FhQm0tRi1NY0VPeU5ZU01vcWoxaldPMFRfMThUNGJRYlpPQzZMX0psRml3UGN6YnEzS2JPdk9BQlUyLWZkNmo0Sms0bjh5LWxCcUoxTEp1SWhsMWJlVTRpWG5rQkdNMk1MSmhkLWtKem9zUzI4UQ?oc=5","date":"2024-09-25","type":"deal","source":"Fierce Biotech","summary":"OncoC4 founders take own science under their wing in new biotech merger - Fierce Biotech","headline":"OncoC4 founders take own science under their wing in new biotech merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOUGFrb21ybVJ5OHpkR0hCUks1NWYzTWpzT2lHNUc1RXA5OTczNWk0MUlNOV9VUlRjNzZYSk1lS21kVG13dDMxUFRscHp5c0RGM1RNZGU0bVF0ZGFBQmdXSTZKRTN3dWh1el82cjROLVJ1QS0zbFVObmFnY2NlaXYwRWxkR3g2VTVjNEhOYzA4aDgxRjIzLUt0X1R5N0ZvTURzMzg2SEw0b0JrcWR5aEE?oc=5","date":"2024-09-25","type":"deal","source":"GlobeNewswire","summary":"OncoC4 and AcroImmune Announce Merger - GlobeNewswire","headline":"OncoC4 and AcroImmune Announce Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZWpFaHZnbUJYUzR5N2ZnSUhISjlDSkFqRU5oN2ZwaV9xU21pVGxhQ2huMTl2eU5BUUdQTDRhRGJJQXNDTUtVUTZlUTVJbm1sbndhRnFZcllmcWFkX2xPQUlVb2FaY3JWbHZtZFRTdVhLQU5QRzNxY092M281QXJkSXJzd1J1Z2U3SHdaaVJnYUdZVUU0cnh3OGVvQ083R0dRMGdlU2NObjhyYXJreXF0VGpmSkJHN0NQLVhsUUtYeEVvNzhTUUZXU2NLaER3cGFMb1pONGl3?oc=5","date":"2023-06-02","type":"trial","source":"Reuters","summary":"BioNTech's OncoC4 partnership off to good start with mid-stage trial results - Reuters","headline":"BioNTech's OncoC4 partnership off to good start with mid-stage trial results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQUi1xMDZ0R1RNbU1ZVHpLOWpOaHRPcUZxVzhuZXVYY1MtZXFMRkh5QVRCSk5lYWd0bDJtOW53YVpzcUdUTVRTTjBTeFlwNHI3cTdSMVBKQUNHRFYxMXdzczM0UTZWY2NpampDTzNjN0loY00wblpvRVFONjk0MVZaTmhqTlQyYlNhdnhzemFNQmFsVVhRaHNKUnFud3VPYThnQVNCZ2twdlIwNmlZeTZvSmdB?oc=5","date":"2023-03-20","type":"deal","source":"Contract Pharma","summary":"BioNTech, OncoC4 Partner to Develop mAb Candidate ONC-392 in Cancer - Contract Pharma","headline":"BioNTech, OncoC4 Partner to Develop mAb Candidate ONC-392 in Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQcG9oZkV4Y01wWVFtZENIV19HeDdoVkswTEVab0xGNkFfNDdHc2tldXZ0S3FxVnV1WXppMkdnQjd1TzJoSjJJcWoyVHBMSVBydFFuMjZpdkk1QlNobXVmeC0wYWlRWV9FcnRHMVpjMTM5LWhMd1lwTkVhSmljb0NfaVN6QUI5OWJ4dEl6LXBtT3ZQZ0Ru?oc=5","date":"2023-03-20","type":"deal","source":"BioPharma Dive","summary":"Flush with cash, BioNTech buys into an immunotherapy to rival Yervoy - BioPharma Dive","headline":"Flush with cash, BioNTech buys into an immunotherapy to rival Yervoy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}